Zelluna Immunotherapy AS logo

Zelluna Immunotherapy AS

Zelluna Immunotherapy, is a biotech company developing T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.zelluna.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Oslo Cancer Cluster Innovation Park Ullernchausséen 64 0379
Oslo
Norway
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/zelluna” connections=”true” suffix=””]

Zelluna is developing a unique portfolio of non-engineered tumor specific T-cell receptors (TCRs) isolated from long term surviving patients from cancer vaccine trials and is developing candidates both for use in adoptive cell therapy (ACT) and as soluble TCRs in combination with a range of effector functions.
Zelluna has access to the large collection of TCRs avaliable at the Radium Hospital. The Immunotherapy Department and the Clinical Trial Units at the Radium Hospital collected biomaterial from long-term survivors for over three decades and this serves as a highly valuable source of material for discovery of tumour antigen specific T cell receptors.

In Mar 2018, Zelluna Immunotherapy appoints MaSTherCell as its contract development and manufacturing (CDMO) partner for the Zelluna TCR adoptive cell therapy platform.

In Feb 2017 The Norwegian Research Council (NRC) has awarded Zelluna Immunotherapy NOK 14 Mn grant, for over a period of 3.5 years through the BIA program for the development of T cell based cancer therapy